Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics PLC is anticipated to experience substantial revenue growth, with projections for fiscal year 2026 estimating sales to reach $167 million, reflecting a significant year-over-year increase of approximately 220%, which surpasses existing consensus estimates. This expected sales acceleration is bolstered by improved margins resulting from increased operational scale, likely leading to enhanced profitability. Additionally, the company's Aucazyl product has demonstrated statistically significant safety improvements, positioning it as a potentially preferred treatment in the landscape of CAR-T therapies for relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

Bears say

The analysis of Autolus Therapeutics indicates a negative outlook due to disappointing early-stage clinical results, specifically concerning the production forecasts for CAR-T therapeutics, which may not meet expectations based on the limited patient cohort data. Investors remain skeptical about the company's ability to achieve break-even, particularly in light of adverse outcomes such as one patient experiencing morphological relapse and another showing emerging minimal residual disease (MRD). Additionally, the sum-of-the-parts (SOTP) analysis reflects cautious sentiment, applying a reduced discount rate to the estimated sales potential, suggesting a diminished confidence in the pipeline's growth trajectory.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.